Last10K.com

Bluebird Bio, Inc. (BLUE) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Bluebird Bio, Inc.

CIK: 1293971 Ticker: BLUE

                                                                         

 

Exhibit 99.1

 

 

bluebird bio Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Progress

 

-- Treated first patient in CRB-401 study of anti-BCMA CAR T bb2121 in relapsed/refractory multiple myeloma --

-- Announced that Celgene has exercised its option to license bb2121 --

-- Presented LentiGlobin clinical data in transfusion-dependent ß-thalassemia and severe sickle cell disease at the American Society of Hematology (ASH) annual meeting --

-- Presented pre-clinical and manufacturing data from oncology pipeline at ASH annual meeting --

-- Signed exclusive license agreement with Viromed for solid tumor CAR T target --

-- Ended year with $865.8 million in cash, cash equivalents, and marketable securities --

 

CAMBRIDGE, Mass., February 24, 2016 – bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2015.

 

“In 2015 bluebird bio defined an accelerated regulatory path for LentiGlobin in ß-thalassemia and established a powerful reason to believe in LentiGlobin in sickle cell disease, though there is still more to learn as we treat additional patients. We also fully enrolled our Starbeam study of Lenti-D in cerebral adrenoleukodystrophy and made significant advances in building a competitive T cell oncology franchise,” said Nick Leschly, chief bluebird. “In 2016 we are excited to learn even more across all of our programs and continue to innovate and improve. We are particularly looking forward to sharing data from the Starbeam study for the first time and presenting more data with longer follow-up from all three of our LentiGlobin clinical studies.”

 

Recent Highlights

 

 

·

ADVANCED FIRST ONCOLOGY PROGRAM INTO THE CLINIC – Earlier in February, the first patient was infused in the CRB-401 study of bb2121 in relapsed/refractory multiple myeloma. Additionally, Celgene has exercised its option to exclusively license bb2121, under the terms of the collaboration agreement between the two companies. bluebird bio will receive a $10.0 million option exercise payment from Celgene and is also eligible to receive specified development and regulatory milestone payments and royalty payments on net sales.

 

 

 

·

PRESENTED UPDATED CLINICAL DATA IN ß-THALASSEMIA FROM HGB-204 AND HGB-205 CLINICAL STUDIES OF LENTIGLOBIN AT ASH – In December 2015, investigators presented data from bluebird bio’s ongoing clinical

 

1

 


The following information was filed by Bluebird Bio, Inc. (BLUE) on Wednesday, February 24, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Bluebird Bio, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bluebird Bio, Inc..

Continue

Assess how Bluebird Bio, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bluebird Bio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit)
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
401(k) Savings Plan
401(k) Savings Plan - Additional Information (detail)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (tables)
Accrued Expenses And Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (detail)
Business Combinations
Business Combinations (tables)
Business Combinations - Additional Information (detail)
Business Combinations - Estimated Fair Value Of Assets Acquired And Liabilities Assumed (detail)
Business Combinations - Schedule Of Acquisition-date Fair Value (detail)
Business Combinations - Schedule Of Estimated Amortization Of Intangible Assets (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Future Minimum Commitments (detail)
Common Stock And Preferred Stock
Common Stock And Preferred Stock (tables)
Common Stock And Preferred Stock - Additional Information (detail)
Common Stock And Preferred Stock - Summary Of Future Issuance Of Common Stock Shares (detail)
Description Of The Business
Description Of The Business - Additional Information (detail)
Fair Value Measurements
Fair Value Measurements (tables)
Fair Value Measurements - Additional Information (detail)
Fair Value Measurements - Recorded Amount Of Assets And Liabilities Measured At Fair Value On Recurring Basis (detail)
Fair Value Measurements - Roll-forward Of Fair Value Of The Company's Contingent Consideration Obligations (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Net Deferred Tax Assets (detail)
Income Taxes - Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate To Effective Income Tax Rate As Reflected In The Financial Statements (detail)
Income Taxes - Schedule Of Components Of Loss Before Income Taxes (detail)
Income Taxes - Summary Of Income Tax Expense (benefit) (detail)
Marketable Securities
Marketable Securities (tables)
Marketable Securities - Summary Of Available For Sale Securities Held (detail)
Net Loss Per Share
Net Loss Per Share (tables)
Net Loss Per Share - Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (detail)
Property And Equipment, Net
Property And Equipment, Net (tables)
Property And Equipment, Net - Additional Information (detail)
Property And Equipment, Net - Property And Equipment (detail)
Restricted Cash
Restricted Cash - Additional Information (detail)
Selected Quarterly Financial Data (unaudited)
Selected Quarterly Financial Data (unaudited) (tables)
Selected Quarterly Financial Data - Quarterly Financial Information (detail)
Selected Quarterly Financial Data - Quarterly Financial Information (parenthetical) (detail)
Significant Agreements
Significant Agreements - Additional Information (detail)
Stock-based Compensation And Warrants
Stock-based Compensation And Warrants (tables)
Stock-based Compensation And Warrants - Additional Information (detail)
Stock-based Compensation And Warrants - Assumptions Used For The Black-scholes Option-pricing Model To Determine The Per Share Weighted Average Fair Value For Options Granted (detail)
Stock-based Compensation And Warrants - Summary Of Restricted Stock Units (detail)
Stock-based Compensation And Warrants - Summary Of Stock Option Activity Under Plan (detail)
Stock-based Compensation And Warrants - Summary Of Stock-based Compensation Expense By Award Type (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies And Basis Of Presentation
Summary Of Significant Accounting Policies And Basis Of Presentation (policies)
Summary Of Significant Accounting Policies And Basis Of Presentation (tables)
Summary Of Significant Accounting Policies And Basis Of Presentation - Additional Information (detail)
Summary Of Significant Accounting Policies And Basis Of Presentation - Estimated Useful Lives Of Assets (detail)
Ticker: BLUE
CIK: 1293971
Form Type: 10-K Annual Report
Accession Number: 0001564590-16-013381
Submitted to the SEC: Thu Feb 25 2016 4:32:14 PM EST
Accepted by the SEC: Thu Feb 25 2016
Period: Thursday, December 31, 2015
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/blue/0001564590-16-013381.htm